In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, published in the "Journal of Hepatology" in 2025.
Learning objectives
- Understand the updated EASL recommendations for initiating and discontinuing antiviral therapy in chronic hepatitis B, including key differences with other HBV guidelines. Participants will be able to identify treatment indications and make informed decisions about when and how to stop antiviral therapy.
- Learn how to monitor patients with hepatitis B across different clinical scenarios, including those not on treatment, those receiving antiviral therapy, surveillance for hepatocellular carcinoma, risk of reactivation, and response to vaccination, in alignment with the new EASL guidelines.
- Explore future directions in the management of chronic hepatitis B as outlined in the EASL guidelines, including advances in nomenclature and antiviral therapies under development.
Faculty
- Markus Cornberg - Moderator
- Maud Lemoine - Speaker
- Sabela Lens - Speaker
- Jerzy Jaroszewicz - Speaker
